2-Tert-butyl-5-chloro-1,3-benzoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-Tert-butyl-5-chloro-1,3-benzoxazole
• 化学式: C₁₁H₁₂ClNO
• 分子量: 209.67
• InChiKey: RYFDIMGJRQZPGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Cook, II James H.

  公开号：US20090270405A1

  公开（公告）日：2009-10-29

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱性α7受体的配体，可能对治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病，有用。
• Novel piperazines, pharmaceutical compositions and methods of use thereof
  申请人：Clark B. Roger

  公开号：US20080051415A1

  公开（公告）日：2008-02-28

  Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

  本发明涉及一种新的哌嗪衍生物，其作为α7 nAChR的激动剂。同时还揭示了制药组合物，治疗炎症疾病的方法，治疗中枢神经系统疾病的方法，抑制哺乳动物细胞细胞因子释放的方法以及制备新化合物的方法。
• Sphingosine Kinase Inhibitors
  申请人：Smith Charles D.

  公开号：US20080167352A1

  公开（公告）日：2008-07-10

  The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  本发明涉及置换的金刚烷化合物，其药物组成物、制备过程以及抑制鞘氨醇激酶、治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
  申请人：Cook, II James H.

  公开号：US20100099684A1

  公开（公告）日：2010-04-22

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  本公开提供公式I的化合物，包括其盐，以及使用这些化合物的组合物和方法。这些化合物是尼古丁α7受体的配体，可能对中枢神经系统的各种疾病，特别是情感和神经退行性疾病的治疗有用。
• Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof
  申请人：Clark Roger B.

  公开号：US20120071652A1

  公开（公告）日：2012-03-22

  Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

  本发明涉及新型哌嗪衍生物，其作为α7 nAChR的激动剂。本发明还涉及制药组合物、治疗炎症性疾病的方法、治疗中枢神经系统疾病的方法、抑制哺乳动物细胞细胞因子释放的方法以及制备新型化合物的方法。